Our view on Resmed (RMD) is different to the other brokers
Michael Gable
Fairmont Equities
Our view on Resmed (RMD) is different to the other brokers. Of the 8 covering it, 7 rate it as a buy, with one neutral. When everyone is bullish, the contrarian trade normally wins out, doesn't it? You can read our views on RMD via the following link: (VIEW LINK) For a copy of the full report containing other trading and investment ideas, visit our website (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian Financial Review, and Sky News Business.
Fairmont Equities provides portfolio management services and also produces weekly investment and trading ideas.
Sign up to our weekly newsletter containing stock tips and educational articles. Head to www.fairmontequities.com and leave your email to sign up now.
Michael Gable
Managing Director
Fairmont Equities
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...
Expertise
No areas of expertise
Michael Gable
Managing Director
Fairmont Equities
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment